On March 1, 2018 Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, reported that it will report fourth quarter and full year 2017 financial results on Thursday, March 8, 2018 (Press release, Jounce Therapeutics, MAR 1, 2018, View Source;p=RssLanding&cat=news&id=2335817 [SID1234524973]). Jounce Therapeutics’ management team will host a live conference call and webcast to discuss these results and provide a corporate update at 8:00 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast
To access the conference call, please dial (866) 916-3380 (domestic) or (210) 874-7772 (international) and refer to conference ID 6198947. The live webcast can be accessed under "Events & Presentations" in the Investors and Media section of the company’s website at www.jouncetx.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days thereafter.

On March 1, 2018 Rubius Therapeutics, a biotechnology company pioneering the creation of a new class of extraordinarily active, ready-to-use and life-changing cellular therapies, reported the successful completion of an oversubscribed $100 million crossover financing (Press release, Rubius Therapeutics, MAR 1, 2018, View Source [SID1234524362]). In just under nine months, the Company has now raised over $220 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Rubius has developed the technology to grow, genetically engineer and mature long-circulating Red-Cell Therapeutics (RCT) products, which have the potential to provide transformational clinical benefits to a wide range of patients across multiple therapeutic areas. These allogeneic, off-the-shelf products offer the additional advantage of extended stability and storage to allow for rapid, universal access by the medical community. Proceeds from the financing will be used to accelerate the development of the Company’s portfolio of RCTs towards clinical proof-of-concept, and to enhance its manufacturing capacity and capabilities.

"The addition of this funding further strengthens our foundation and enables us to accelerate the development of our first wave of RCT products that are targeting treatment of enzyme deficiencies, cancer and autoimmune disease," said Torben Straight Nissen, Ph.D., President of Rubius Therapeutics. "We have assembled an extremely talented team of investors, leadership and advisors, which all share the long-term vision of bringing novel cellular therapies to patients."

"We are pleased with the quality of the investor group participating in this financing, and would like to thank our new and existing investors," said David Epstein, Executive Chairman of Rubius and Executive Partner of Flagship Pioneering. "Their strong support further validates the potential of RCT products and the opportunity that we have to make a meaningful impact in the lives of patients."

"Rubius has become one of the most exciting members of the Flagship family of companies; applying scientifically disruptive insights against unsolved problems to create groundbreaking new therapies," said Noubar Afeyan, CEO of Flagship Pioneering and Co-Founder of Rubius. "We are excited to further support Rubius in this crossover round as the company continues to advance the next generation of cellular therapies."

On March 1, 2018 Cullgen Inc. reported a Series Seed Financing of up to $15M by GNI Group Ltd. (GNIG) (TOKYO: 2160) to build a new drug discovery platform based on advanced ubiquitin-mediated protein degradation technology (Press release, Cullgen, MAR 1, 2018, View Source [SID1234524361]). In addition to GNI USA, Inc., the Company founders are Dr. Yue Xiong, William R. Kenan Professor of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, and Dr. Jian Jin, Professor of Pharmacological Sciences, Icahn School of Medicine, Mount Sinai, New York. The Company is incorporated in Delaware, USA and will concurrently initiate research operations in the United States, Japan and China.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cullgen’s technology focuses on selective degradation of disease-causing proteins, including targets previously considered undruggable. This technology can provide scientists with new means to develop novel therapeutic approaches for various diseases. Since 1998, Dr. Xiong has been among the first to discover the catalytic and regulatory components and the assembly mechanism of the cullin-RING family of E3 ubiquitin ligases, enzymes that comprise the basis of Cullgen’s technology platform. During the past several years, Dr. Jin and Dr. Xiong have successfully developed many new chemical entities (NCEs) against different cancer targets, which has resulted in multiple patent applications. This new drug discovery platform has the advantage of accelerating NCEs into clinical development in a cost and time efficient manner to benefit patients. Initial drug discovery programs will focus on oncology and expand into areas such as inflammatory and autoimmune diseases.

To-date, Cullgen has invited Dr. Lisa Carey, Dr. Stephen Frye, and Dr. Peter Jackson, to join the company’s scientific advisory board. They bring extensive experience and achievements in medical oncology, drug discovery and ubiquitin research.

Cullgen’s Board of Directors includes Dr. Ying Luo, President and CEO of GNIG, Dr. Yue Xiong, Dr. Jian Jin, and Mr. Thomas Eastling, CFO of GNIG. Other board members and corporate executives will be appointed in the future.

ON March 1, 2018 Abbott (NYSE: ABT) reported that it will participate in the Barclays Capital Global Healthcare Conference on Wednesday, March 14, 2018 (Press release, Abbott, MAR 1, 2018, View Source [SID1234524286]). Brian Yoor, executive vice president, finance and chief financial officer, will present at 2:20 p.m. Central time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast will be accessible through Abbott’s Investor Relations website at www.abbottinvestor.com.

On March 1, 2018 Exact Sciences Corp. (Nasdaq: EXAS) reported that company management will be presenting at the following investor conferences during March and invited investors to participate by webcast (Press release, Exact Sciences, MAR 1, 2018, View Source [SID1234524348]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cowen 38th Annual Health Care Conference, Boston
Fireside Chat on March 12 at 4:50 p.m. Eastern time
Barclays Capital Global Healthcare Conference, Miami
Presentation on March 15 at 9:30 a.m. Eastern time

The webcasts can be accessed in the investor relations section of Exact Sciences’ website at www.exactsciences.com.